Articles tagged with Stem Cell Therapy
Researchers have generated functional human liver cells from stem cells and transplanted them into mice with acute liver injury. The stem-cell derived human liver cells were able to function normally and increase the survival of treated animals. This breakthrough demonstrates a scalable method for producing these cells, which could lea...
A UC Davis study reveals that astrocytes can protect brain tissue and reduce disability due to stroke. The research found that a specific type of astrocyte called Olig2PC-Astros has greater antioxidant effects and improves learning and memory in rats.
A new gene therapy approach using a partially inactivated lentivirus has shown significant improvement in three children with Wiskott-Aldrich Syndrome. The therapy corrects the genetic defect in blood cells by introducing a normal WASP gene, reducing the risk of cancer-promoting genes.
Researchers from the University of Toronto have identified key proteins that control pluripotency, a crucial step in producing induced pluripotent stem cells (iPSCs) for research and therapy. The discovery could lead to a more efficient production method for these cells, which can develop into many different cell types.
Researchers have developed a rapid and reliable technique to identify mice with specific gene deletions or replacements, using polymerase chain reaction (PCR). This method will provide a valuable tool for researchers studying bone marrow reconstitution and TCR/CD3 retrogenesis.
A study published in Stem Cell Research and Therapy found that grafting fetal human stem cells into the spine improves both motor and sensory functions, as well as structural integrity, in rats with acute lumbar compression injuries. The researchers also observed long-term improvements in spinal cord segments.
Research published in BioMed Central's Stem Cell Research & Therapy found that injecting human stem cells into mice with tumors slowed down tumor growth. The study suggests that stem cells may restrict oxygen and nutrient delivery to the tumor, limiting cell division.
A first-in-humans study demonstrates that cardiopoietic stem cell therapy can improve heart pumping function and fitness in heart failure patients. Patients in the treatment group experienced a significant improvement in ejection fraction, compared to those in the control group.
Researchers developed a tunable process that separates human induced pluripotent stem cells (hiPSCs) based on their adhesive properties. The method allows for high-throughput separation and produces pure cultures with up to 99% hiPSC purity, enabling improvements in cell reprogramming and disease modeling.
The new guidelines aim to personalize therapy for patients with multiple myeloma by separating them into three risk groups: high, intermediate, and low. This approach allows for more tailored treatment plans that balance benefits with short- and long-term toxicity, ultimately improving patient outcomes.
Scientists at the University of York have discovered a cancer-inducing DNA realignment in human prostate cancer stem cells that can lead to more effective therapies targeting the root cause of the disease. This breakthrough has challenged previous understanding of solid cancers and offers new opportunities for targeted treatments.
A team of researchers has discovered multipotent stem cells in deer antlers, which can differentiate into multiple cell types and have the potential to treat various injuries in veterinary medicine. The study highlights a novel source of stem cells for use in regenerative therapies.
Scientists have developed a web-like scaffold coated with long-sugar molecules that enhances stem-cell cultures and encourages the formation of neuronal cell types. The results, published in the Journal of Biological Chemistry, are promising for treating diseases such as Alzheimer's and diabetes.
Researchers at Johns Hopkins University have discovered a key protein that antidepressants and electroconvulsive therapy target to relieve depression by stimulating stem cells in the brain. This finding could lead to genetic tests to predict individual responses to therapy and develop new treatments.
Researchers found that stem cell therapy stimulates the heart's natural repair mechanism, boosting production of adult heart cells and recruitment of existing stem cells. The treatment enhances heart structure and function, with new muscle formed being functional and durable.
A study published in BioMed Central's Stem Cell Research & Therapy journal found that stem cells from bone marrow or fat improved brain and nerve repair after stroke in rats. The treated animals showed significant functional recovery, even without the stem cells migrating to the damaged area.
Scientists at the University of Granada have found that only a specific group of cord blood stem cells (CB-SC) maintained in culture are useful for therapeutic purposes. The researchers identified Wharton's jelly stem cells (HWJSC) as the most suitable subgroup, which can develop into several types of tissue and modulate immune responses.
Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study reveals a connection between Lin28 and BMP4, which has implications for developing novel targeted therapies.
A study published in PNAS reveals that inflammation enhances the activity of enzyme ADAR1, leading to increased self-renewal and therapeutic resistance in cancer stem cells. Targeting this pathway with a small molecule inhibitor may help prevent relapse and progression of chronic myeloid leukemia.
Researchers at the Salk Institute developed a new technique called indirect lineage conversion (ILC), which allows for faster and safer production of stem cells. ILC reduces production time by over half, from two months to two weeks, and increases cell yields, making it a promising step towards regenerative medicine therapies.
A new therapeutic technique repairs and rebuilds skeletal muscle using a combination of mesoangioblast stem cells and hydrogel cell-carrier matrix. The study demonstrates improved engraftment, survival, and integration of the stem cells into regenerating muscle fibers.
Researchers at Beth Israel Deaconess Medical Center have discovered how MSCs traffic from circulation to damaged tissues, revealing a rate-limiting step that may explain their inefficiency in entering inflamed areas. The findings suggest enhancing MSC homing could improve delivery and therapeutic efficacy.
Researchers explored the benefits of adding radionuclide therapy to cancer treatment regimens for patients with advanced disease. Studies found improved tumor control rates and longer patient survival without significant side effects, suggesting a potential paradigm shift in cancer control.
New animal studies demonstrate potential for stem cell treatments in Parkinson's disease, head trauma and spinal cord injury-related heart problems. Scientists are making progress toward using stem cells to repair neurological damage and produce healthy neurons.
Scientists at the University of Maryland School of Medicine created a stem cell model for Gaucher disease, allowing them to test potential therapies in a dish. The study uses genetically similar stem cells that react to drugs like patient cells, accelerating drug discovery and bringing hope to patients.
A Phase II intra-arterial stem cell trial has demonstrated the safety of a regenerative therapy in patients with ischemic stroke. The ALD-401 therapy uses patient-derived bone marrow stem cells to promote brain repair after stroke.
A Phase II clinical trial led by Amir Toor shows promise in providing lasting protection against multiple myeloma progression after a stem cell transplant. The therapy forces cancer cells to express proteins that immune system cells can recognize as foreign, boosting the production of T-cell lymphocytes.
Researchers at Mayo Clinic have developed a way to detect and eliminate potentially troublemaking stem cells, making stem cell therapy safer. The new approach uses a chemotherapeutic agent that selectively damages the DNA of the stem cells, efficiently killing the tumor-forming cells without affecting healthy ones.
Researchers develop refined gene therapy approach that safely restores the immune system of children with ADA-deficient SCID. Chemotherapy conditioning regimen prior to treatment significantly increases ADA enzyme levels and partial immune reconstitution in patients.
Researchers at Cedars-Sinai Heart Institute will study the cellular mechanisms behind an experimental stem cell therapy that regenerates healthy muscle in damaged hearts. The treatment has shown promising results, with a 50% reduction in scar size and improved cardiac regeneration.
Researchers at the Stowers Institute for Medical Research discovered that planarian stem cells, known as neoblasts, can mobilize and rebuild tissues lost to amputation. The team found that these stem cells remain pluripotent even in fully mature animals and migrate to the site of injury when needed.
New research reveals that fat-derived stem cells secrete VEGF and other factors that inhibit cartilage regeneration. Pre-treating the cells with antibodies against VEGF can neutralize these effects, promoting chondrocyte survival and cartilage repair.
A new technique using amniotic fluid stem cells can regenerate damaged urethral sphincter muscles and prevent pressure incontinence in mice. Researchers found that the stem cells induced regeneration of the mouse's own urethral sphincter muscle with proper nerve connections.
Researchers at Duke University Health System have found that mesenchymal stem cells can prevent post-traumatic arthritis in mice with fractures. The study suggests that these stem cells alter the balance of inflammation and regeneration in knee joints, thereby preventing the development of osteoarthritis.
Researchers at Cedars-Sinai Medical Center are developing a new treatment for ALS using a combination of stem cells and gene therapy. The grant will fund an 18-patient clinical trial for ALS in four years, with the potential to protect damaged motor neurons and deliver the protein GDNF exactly where it's needed.
Researchers used bioluminescence imaging to track hair follicle stem cells in mice, showing successful regeneration of new hair follicles. The study paves the way for future clinical trials to test the efficacy of this novel therapy for human hair regeneration.
Dr. Patricia Dickson's research aims to develop a stem cell-based therapy for mucopolysaccharidosis I, a fatal pediatric disease causing neurodegeneration. The project seeks to address critical issues in the development of therapeutic candidates.
A Phase III clinical trial found lenalidomide treatment decreased the risk of progressive myeloma or death in stem cell transplant patients, with a 63 percent reduction in disease progression risk. The study's results support the use of lenalidomide maintenance therapy after stem cell transplantation to improve patient outcomes.
The University of Louisville has established a cardiac clinical research center thanks to a $3.4 million NIH grant. Researchers will test the safety and effectiveness of adult stem cell therapies for cardiovascular disorders.
A combination approach therapy targeting β-catenin pathway may stamp out CML for good. Leukemia stem cells are vulnerable to treatments aiming at this pathway, unlike normal blood stem cells.
A recent study has created motor neurons using skin cells from a patient with inherited MND, discovering abnormalities in protein TDP-43 that lead to motor neuron cell death. This breakthrough model could speed up the discovery of new treatments for the devastating disease.
Researchers are using pond scum microbes called Euglena to develop a new test for detecting cancer cells in the bloodstream. The test uses the microbe as a natural cargo carrier to identify and analyze circulating tumor cells, which enable cancer to spread.
A new study found that using a patient's own bone marrow cells can help repair damaged areas of the heart caused by heart failure. The treatment increased left ventricular ejection fraction by a small but significant amount, and improved perfusion defects in patients with chronic ischemic heart disease.
The FOCUS trial found that patients with chronic ischemic heart disease who received stem cell therapy had a significant increase in left ventricular ejection fraction, with improvements correlated to the number of progenitor cells in their bone marrow. This study provides valuable insights for future therapies and trials.
A symposium on TMJ stem cell biology and engineering presents novel clinical therapy approaches for TMJ disorders. Researchers discuss the origin, homeostasis, differentiation, hormonal regulation, and bioengineering of temporomandibular joint tissues.
Using bone marrow-derived mesenchymal stem cells instead of antibody induction therapy reduces acute rejection, opportunistic infections, and improves estimated kidney function at 1 year. Autologous MSC infusion is a promising alternative to traditional immunosuppressive protocols.
A phase I clinical trial led by Ottawa researchers will test the safety and efficacy of mesenchymal stem cells in treating septic shock. The study aims to evaluate the therapy's effects on up to 15 patients with septic shock, who will receive standard treatments plus a planned dose of MSCs.
Effective regenerative therapies for heart disease hinge on collaboration between multiple specialties, including cardiovascular medicine and device technology. Recent advances in cardiac stem cell and regenerative biology are yielding potential new targets and treatment strategies.
Researchers found that fat-derived stem cells thrive on stiff surfaces and form myotubes when matured, a crucial step in muscle development. These cells may offer new therapeutic possibilities for muscular dystrophy patients.
A new method uses stem cells from cord blood to re-educate a diabetic's own T cells, restarting pancreatic function and reducing the need for insulin. After two to three hours, the re-educated lymphocytes are returned to the patient, improving C-peptide levels and allowing for reduced insulin doses.
Scientists developed a way to deliver therapeutic human cells to diseased areas using superparamagnetic iron oxide nanoparticles. The new process, reported in ACS' journal Langmuir, successfully attaches these nanoparticles to the outside of human cells without causing damage.
A study found that a combined immunosuppressive regimen improved the survival of human spinal stem cells in ALS rats. The results suggest that this treatment approach may be a potential therapy for ALS, a degenerative neurological disease.
Researchers have developed a therapy using FT1050 that improves stem cell engraftment in umbilical cord blood transplant recipients, allowing for faster recovery and reduced complications. The treatment accelerates the process of stem cells taking root in patients, resulting in improved outcomes.
Researchers found that reducing CXCR4 levels correlated with reduced infarct size and inflammation, but impaired recovery of blood flow and neovascularization. The study suggests that localized approaches, such as injecting stem cells with higher CXCR4 levels or CXCL12 variants, may be more effective in heart repair.
A new clinical trial funded by NIH found that delayed stem cell therapy after a heart attack is safe, but it does not improve heart function six months later. The study suggests future clinical benefits may still be possible.
A Mayo Clinic study found that stem cells delivered two to three weeks after a heart attack do not improve heart function. The research provides vital information for the field of cell therapy and cautions against seeking stem cell treatment outside the US.
Researchers have combined gene therapy and stem cell transplantation to successfully reverse hemophilia A in large animals, eliminating symptoms and restoring normal activity. However, the treatment's effects may be reduced or shorter due to an immune response developed by the treated animals.
Scientists have cleanly corrected a human gene mutation in a patient's stem cells, using cutting-edge methods to target and correct the sequence of the genome. The corrected gene worked normally, demonstrating the potential for patient-specific therapies.
Professor Peter J. Coffey's pioneering stem cell research aims to replace damaged retinal pigment epithelium cells in Age-Related Macular Degeneration. Clinical trials using his therapy are expected to begin in 2012, offering hope for preventing blindness and restoring sight.
Researchers successfully expanded hematopoietic stem cells a hundredfold by understanding the molecular mechanisms of self-renewal. The study reveals that proliferation, suppression of differentiation and programmed cell death are required for self-renewal.